The formation of a tumor-associated vascular network is an important step in understanding
the stages of tumor progression. This review aims to highlight the main markers of induction, proliferation
and inhibition of angiogenesis, as well as the quantification of microvessel density, correlated
with preclinical and clinical research in gynecologic cancers and also discussed related patents. Studies show that in the
most advanced cases of gynecological cancers, biomarkers such as VEGF (Vascular Endothelial Growth Factor), MMP
(Matrix Metalloproteinase), CD105 (Endoglin), TIMP (tissue inhibitors of metalloproteinases) and VASH (Vasohibin) are
more expressed compared to healthy individuals. Continuous evaluation of these biomarkers in cancer cases could serve
in the future as a basis for development of new therapeutic approaches, leading to a good response to cancer treatment,
and thus increase survival of cancer patients.
Keywords: Angiogenesis, biomarkers, endoglin, gynecologic cancer, microvessel density, VEGF.
Rights & PermissionsPrintExport